PatientsVille.com Logo


Cytotoxic Medical Research Studies

Up-to-date List of Cytotoxic Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Cytotoxic Medical Research Studies

Rank Status Study
1 Recruiting Study of Donor Derived, Multi-virus-specific, Cytotoxic T-Lymphocytes for Relapsed/Refractory Neuroblastoma
Condition: Neuroblastoma
Intervention: Biological: Tri-virus specific Cytotoxic t-cells
Outcome Measures: Infusional and long term safety and persistence of tumor redirected, genetically modified, donor derived, allogeneic multi-virus specific Cytotoxic T-cells (tV-CTL) after allogeneic hematopoietic stem cell transplant in patients with neuroblastoma;   Evaluating the survival, expansion, anti-viral and anti-tumor function of infused tV-CTL after allogeneic transplant in patients with neuroblastoma;   Comparing the frequency and expansion of allogeneic, tumor redirected, multi-virus Cytotoxic T-cells to that of identically transduced, autologous EBV-specific T-cells infused in prior studies.;   Comparing anti-viral immunity after infusion of gene modified, multi-virus specific T-cells to that of patients receiving viral-specific T-cells without gene modification following allogeneic transplant
2 Recruiting Autologous/Allogeneic TGFbeta-resistant LMP2A-specific CTL, Lymphoma (TGF-beta)
Conditions: Lymphoma;   Hodgkin's Disease;   Relapse;   Lymphoma, Non-Hodgkin
Intervention: Genetic: TGFbeta resistant LMP-specific CTLs
Outcome Measures: Safety and MTD of 2 IV injections of autologous/syngeneic or allogeneic TGFb resistant LMP2A-specific Cytotoxic T-lymphocytes.;   Survival and immune function of TGFbeta-resistant LMP-specific Cytotoxic T-lymphocytes;   determine anti-viral and anti-tumor effects of TGFbeta resistant LMP-specific CTL
3 Recruiting Cytotoxic T Cells to Prevent Virus Infections
Conditions: CMV;   EBV;   Adenovirus Infections
Intervention: Drug: Cytotoxic T lymphocytes (CTLs).
Outcome Measures: To assess the safety of administration of CTLs;   Viral load
4 Recruiting Using Multi-virus Cytotoxic T-cells Following T-Cell Depleted Allogeneic HPCT for Prophylaxis Against Epstein Barr Virus, Adenovirus, And Cytomegalovirus
Conditions: Epstein-Barr Virus Infections;   Adenovirus;   Cytomegalovirus Infections
Intervention: Biological: Cytotoxic T Lymphocytes
Outcome Measures: To assess toxicity by SAEs scored according to the adaptive CTCAE version 4;   Evidence of immunity against specific viral pathogens- Ad, CMV and EBV in recipients of Multi-Virus CTLs;   The incidence of Ad, EBV, and CMV systemic infections during the first 180 days post-transplant
5 Recruiting ARMS - Rapidly Generated Multivirus-Specific CTLs for the Prophylaxis And Treatment of EBV, CMV, Adenovirus, HHV6, and BK Virus
Condition: Viral Infection
Intervention: Biological: Multi-virus-specific Cytotoxic T lymphocytes
Outcome Measures: Patients with acute GvHD grades III-IV within 42 days of the last dose of CTLsinfusion;   Patients with grades 3-5 infusion-related adverse events within 30 days of the last CTL dose;   Patients with grades 4-5 nonhematological adverse events within 30 days of the last CTL dose;   Assessment of viral load response to the CTL infusion;   Reconstitution of antiviral immunity
6 Not yet recruiting TGF-beta Resistant Cytotoxic T-lymphocytes in Treatment of EBV-positive Nasopharyngeal Carcinoma / RESIST-NPC
Condition: EBV-positive Nasopharyngeal Carcinoma
Intervention: Genetic: DNR.NPC-specific CTLs
Outcome Measures: Number of subjects with a dose limiting toxicity;   Amount of T cells in the blood after the infusions
7 Recruiting CMV-specific Cytotoxic T Lymphocytes Expressing CAR Targeting HER2 in Patients With GBM
Condition: Glioblastoma Multiforme (GBM)
Intervention: Genetic: Genetically modified HER.CAR CMV-specific CTLs
Outcome Measures: Number of subjects with dose limiting toxicity after CTL infusion;   Decrease in tumor after the CTL infusion;   Area under the growth curves (AUC) over time for T cell frequencies.
8 Recruiting Specific Cytotoxic T-Lymphocytes, EBV-positive Lymphoma, GRALE
Conditions: Hodgkin's Disease;   Non-Hodgkin's Lymphoma;   Lymphoproliferative Disease;   Lymphoma
Interventions: Biological: LMP, BARF1 & EBNA1 specific CTLs: A;   Biological: LMP, BARF1 & EBNA1 specific CTLs : B
Outcome Measures: Assessment of toxicity of escalating doses of LMP, BARF1 and EBNA1 CTLs;   Determine survival and immune function of LMP/BARF1/EBNA1-specific Cytotoxic T-lymphocyte lines;   Assess anti-viral and anti-tumor effects of LMP/BARF1/EBNA1-specific CTL;   Obtain preliminary information on safety and response to extended dosage regimen
9 Recruiting In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the B-Cell Specific Antigen CD19 Positive Residual Or Relapsed Acute Lymphoblastic Leukemia After Allogeneic Hematopoietic Progenitor Cell Transplantation
Condition: Acute Lymphocytic Leukemia
Intervention: Biological: Biological/Genetically Modified T cells
Outcome Measures: Evaluate the safety/persistence of escalating doses of allogeneic EBV specific CTL modified to express artificial T cell receptors targeting CD19 molecule given for persistence or relapse of B-Cell ALL post allogeneic HSCT.;   To assess the effects of the adoptively transferred CD19 specific T-cells on the progression of leukemia.;   To quantitate the number of chimeric antigen receptor (CAR) positive T-cells in the blood at defined intervals post infusion in order to determine their survival and proliferation in the host.;   To assess long-term status of treated patients
10 Recruiting Cytotoxic T Cells to Treat Relapsed EBV-positive Lymphoma
Conditions: Hodgkin Disease;   Non Hodgkin Lymphoma;   Lymphoepithelioma;   Severe Chronic Active EBV Infection Syndrome (SCAEBV);   Leiomyosarcoma
Interventions: Drug: LMP1/2 CTLs (Group A);   Drug: LMP1/2 CTLs (Group B)
Outcome Measures: Number of patients with dose limiting toxicity (DLT);   Survival and Immune Function of LMP-specific CTLs
11 Recruiting Allogeneic Multivirus - Directed Cytotoxic T Lymphocytes (CTL)
Conditions: EBV;   CMV;   Adenovirus
Interventions: Drug: CTL for CMV seropositive donors;   Drug: CTL for CMV naïve donors
Outcome Measures: Assessments of patients with adverse events after mukti-virus specific CTL infusion.;   Assessments of viral load response to the CTL infusion
12 Available Allogeneic Virus-Specific Cytotoxic T-Lymphocytes(CTL), Persistent/Recurrent Viral Infection Post-HSCT (EAP CHALLAH)
Conditions: EBV Infection;   CMV Infection;   Adenoviral Infection
Intervention: Biological: Trivirus-Specific CTLs
Outcome Measure:
13 Recruiting An Open-Label, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetics of VX-970 in Combination With Cytotoxic Chemotherapy
Condition: Advanced Solid Tumor
Interventions: Drug: VX-970;   Drug: gemcitabine;   Drug: cisplatin;   Drug: etoposide
Outcome Measures: Safety parameters, including adverse event (AEs), clinical laboratory values (serum chemistry, hematology, and urinalysis), vital signs, and electrocardiogram (ECG) assessments;   Maximum tolerated dose (MTD) of VX-970 administered in combination with cisplatin and gemcitabine and in combination with gemcitabine;   Maximum tolerated dose (MTD) of VX-970 in combination with cisplatin and in combination with cisplatin and etoposide;   PK parameter estimates of VX-970 derived from whole blood and/or plasma concentration-time data;   PK parameter estimates of etoposide derived from plasma concentration-time data after coadministration with VX-970 and in the absence of VX-970;   Objective tumor response (OR) as evaluated by CT scan and quantified by Response Criteria Evaluation (Response Evaluation Criteria in Solid Tumors - RECIST);   Progression-free survival (PFS) and Overall (OS) by time after initiation of treatment
14 Recruiting Allogeneic Stem Cell Transplantation With Adoptive Immunotherapy in Epstein-Barr Virus Positive Recurrent/Refractory Hodgkins Lymphoma
Condition: Hodgkins Lymphoma
Intervention: Biological: allogeneic donor derived LMP specific Cytotoxic T-lymphocyte
Outcome Measures: Safety;   Toxicity;   Feasibility
15 Recruiting Giving Epstein-Barr Virus (EBV) Specific Killer T Lymphocytes to Patients Who Have Had Donor Marrow Grafts
Condition: Epstein-Barr Virus Infections
Intervention: Biological: EBV specific T cells
Outcome Measures: Safety of one intravenous injection of BMT donor derived EBV specific Cytotoxic T lymphocytes (CTLs) in BMT recipients at high risk.;   To compare the antiviral and immunological efficacy of a single dose of CTLs compared to the multiple dose regimens previously employed
16 Recruiting Nivestim(TM) in Treatment of Malignant Diseases
Conditions: Solid Tumor;   Malignant Hematological Tumor;   Primary or Secondary Prophylactic Treatment
Outcome Measures: Number of hospitalizations;   Number of adverse events;   Changes to efficacy parameters from baseline to 6 months
17 Recruiting Most Closely HLA-Matched CTLs for Relapsed Epstein Barr Virus(EBV)-Associated Diseases
Conditions: Hodgkin Lymphoma;   Non-Hodgkin Lymphoma;   Lymphoproliferative Disorder;   Nasopharyngeal Carcinoma;   Leiomyosarcoma;   Severe Chronic Active EBV (SCAEBV)
Intervention: Biological: LMP specific T cells
Outcome Measures: Patients with dose limiting toxicities after T-cell infusions;   Safety and response to a repeated dosage regimen;   Analysis of immune function of CTLs;   Number of patients with an EBV and/or disease response to the CTLs
18 Recruiting Multi-virus CTLs Expressing CD19 Chimeric Receptors, CD19 Positive Malignancies Post SCT, MULTIPRAT
Conditions: Acute Lymphoblastic Leukemia (ALL);   Chronic Lymphocytic Leukemia (CLL);   Non Hodgkin's Lymphoma
Intervention: Genetic: CD19CAR/virus specific T cells
Outcome Measures: Number of dose limiting toxicities;   Tumor response to gene modified CTL on measurable disease.;   Frequency of T-cells expressing gene-modified CTLs.;   Frequency of CD19+ B-Cells post HSCT expressing gene-modified CTLs
19 Recruiting Microparticle Enhanced Cytotoxic Transarterial Embolization Therapy in Hepatocellular Carcinoma
Condition: Hepatocellular Carcinoma
Intervention: Device: TANDEM™
Outcome Measures: Number of Patients with SAEs;   Tumor Progression;   Local Tumor control
20 Recruiting Sodium Selenite as a Cytotoxic Agent in Advanced Carcinoma
Conditions: Malignant Tumor;   Treatment Resistant Disorders;   Tumor Progression
Interventions: Drug: Sodium selenite (Introselen);   Drug: Sodium selenite
Outcome Measures: Maximal tolerable dose (phase I, ongoing);   Responses

These studies may lead to new treatments and are adding insight into Cytotoxic etiology and treatment.

A major focus of Cytotoxic research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.

Discuss Cytotoxic